title: Post-chemotherapy retroperitoneal teratoma in nonseminomatous germ cell tumors: Do predictive factors exist? Results from a national multicenter study.
abstract: OBJECTIVE
  To identify predictive preoperative factors of the presence of teratoma in retroperitoneal lymph node dissection specimens.
  
  
  METHODS
  We performed a 20 years multicenter retrospective analysis of all patients who underwent retroperitoneal lymph node dissection for residual masses after chemotherapy (PC-RPLND). Patients had undergone PC-RPLND after chemotherapy for advanced testicular cancer. The histologic components of the primary tumor were compared with those of the residual masses using logistic regression.
  
  
  RESULTS
  A total of 469 NSGCT patients underwent PC-RPLND (complete data available for 211). By PC-RPLND, necrosis was found in 84 cases, teratoma in 102 cases, and viable tumor in 25 cases. The univariate and multivariate analyses showed that teratoma (P = 0.001 and P = 0.002, respectively) and yolk sac tumor (P = 0.009 and P = 0.035, respectively) in orchiectomy specimens were statistically significant predictors of the presence of teratoma in retroperitoneal lymph nodes.
  
  
  CONCLUSIONS
  PC-RPLND is the standard treatment for any supracentimetric residual lesion. This procedure is associated with a high morbidity, and almost half patients are overtreated. The presence of teratoma and yolk sac tumor in the orchiectomy specimen were independent significant predictors of teratoma in retroperitoneal masses. J. Surg. Oncol. 2016;114:992-996. © 2016 Wiley Periodicals, Inc.
authors.affiliation: Department of Urology, Hopital d'Instruction des Armees Begin, Saint Mandé, France.
authors.forename: Marie
authors.initials: M
authors.lastname: Dusaud
authors.affiliation: University Hospital of Toulouse, Toulouse, France.
authors.forename: Bernard
authors.initials: B
authors.lastname: Malavaud
authors.affiliation: Department of Urology, Hopital d'Instruction des Armees Begin, Saint Mandé, France.
authors.forename: Younes
authors.initials: Y
authors.lastname: Bayoud
authors.affiliation: Hopital Tenon, Paris, France.
authors.forename: Philippe
authors.initials: P
authors.lastname: Sebe
authors.affiliation: Clinic Saint Augustin Bordeaux, Bordeaux, France.
authors.forename: Jean Luc
authors.initials: JL
authors.lastname: Hoepffner
authors.affiliation: Hopital Henri Mondor, Creteil, France.
authors.forename: Laurent
authors.initials: L
authors.lastname: Salomon
authors.affiliation: Hopital d'Instruction des Armees du Val-de-Grace, Paris, France.
authors.forename: Alain
authors.initials: A
authors.lastname: Houlgatte
authors.affiliation: University Hospital of Kremlin Biêtre, Paris, France.
authors.forename: Géraldine
authors.initials: G
authors.lastname: Pignot
authors.affiliation: Jules Verne Clinic of Nantes, Nantes, France.
authors.forename: Jérome
authors.initials: J
authors.lastname: Rigaud
authors.affiliation: Centre Leon Berard, Lyon, France.
authors.forename: Aude
authors.initials: A
authors.lastname: Fléchon
authors.affiliation: Centre Hospitalier Universitaire de Rouen, Rouen, France.
authors.forename: Christian
authors.initials: C
authors.lastname: Pfister
authors.affiliation: Hopital Pitie-Salpetriere, Paris, France.
authors.forename: Morgan
authors.initials: M
authors.lastname: Rouprêt
authors.affiliation: University Hospital of Toulouse, Toulouse, France.
authors.forename: Michel
authors.initials: M
authors.lastname: Soulié
authors.affiliation: Hopital Europeen Georges Pompidou, Paris, France.
authors.forename: Arnaud
authors.initials: A
authors.lastname: Méjean
authors.affiliation: Department of Urology, Hopital d'Instruction des Armees Begin, Saint Mandé, France.
authors.forename: Xavier
authors.initials: X
authors.lastname: Durand
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000627:therapeutic use; D006801:Humans; D016015:Logistic Models; D008197:Lymph Node Excision; D008198:Lymph Nodes / Q000473:pathology* / Q000601:surgery; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009373:Neoplasms, Germ Cell and Embryonal / Q000188:drug therapy / Q000473:pathology* / Q000601:surgery; D009919:Orchiectomy; D012186:Retroperitoneal Neoplasms / Q000209:etiology / Q000473:pathology* / Q000601:surgery; D012187:Retroperitoneal Space; D012189:Retrospective Studies; D012307:Risk Factors; D013724:Teratoma / Q000473:pathology* / Q000601:surgery; D013736:Testicular Neoplasms / Q000188:drug therapy / Q000473:pathology* / Q000601:surgery; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D002945:Cisplatin
keywords: chemotherapy; retroperitoneal lymph node dissection; teratoma; testicular neoplasm